POOJA JAISWAL¹, VERSHA TRIPATHI¹, ANSHUL ASSAIYA², DHARMENDRA KASHYAP³, RAHUL DUBEY⁴, ANAMIKA SINGH⁴, JANESH KUMAR², HEM CHANDRA JHA³, RAJESH SHARMA⁵, AMIT KUMAR DIXIT⁶, HAMENDRA SINGH PARMAR^1,*

BIOCELL, Vol.46, No.12, pp. 2645-2657, 2022, DOI:10.32604/biocell.2022.021754

Abstract Triple-negative breast cancer (TNBC) cell line MDA-MB-231 is known for Warburg metabolism and defects in mitochondria. On the other hand, dipeptidyl peptidase-IV (DPP-IV) inhibitors such as sitagliptin and vildagliptin and GLP-1 agonist exendin-4 are known to improve mitochondrial functions as well as biogenesis, but no study has evaluated the influence of these drugs on mitochondrial biogenesis on metastatic breast cancer cell line. We have recently reported anticancer effects of 5-aminoimidazole-4-carboxamide riboside on MDA-MB-231 cells via activation of AMP-dependent kinase (AMPK), which activates the downstream transcription factors PGC-1α, PGC-1β, or FOXO1 for mitochondrial biogenesis; above-mentioned incretin-based therapies are also known to… More >

ATTALLA F. EL-KOTT^1,2,*, AYMAN E. EL-KENAWY³, EMAN R. ELBEALY⁴, ALI S. ALSHEHRI¹, HEBA S. KHALIFA², MASHAEL MOHAMMED BIN-MEFERIJ⁵, EHAB E. MASSOUD^6,7,8, AMIRA M. ALRAMLAWY⁹

BIOCELL, Vol.45, No.5, pp. 1337-1353, 2021, DOI:10.32604/biocell.2021.015464

Abstract This study examined if the anti-tumorigenesis effect of Exendin-4 in HT29 and HCT116 colorectal cancer (CRC) involves modulation of SIRT1 and Akt/GSR3K/β-catenin/NF-κB axis. HT29 and HCT116 cells were treated either with increasing levels of Exendin-4 (0.0-200 µM) or with Exendin-4 (at its IC₅₀) in the presence or absence of EX-527 (10 µM/a selective SIRT1 inhibitor) or Exendin-4 (9-39) amide (E (9-39) A) (1 µM/an Exendin-4 antagonist). In a dose-dependent manner, Exendin-4 inhibited cell survival, but enhanced levels of lactate dehydrogenase (LDH) and single-stranded DNA (ssDNA) in both HT29 and HCT116. In both cell lines and at it has an IC₅₀… More >